ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

ClinicalTrials.gov ID: NCT04800237

Public ClinicalTrials.gov record NCT04800237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety

Study identification

NCT ID
NCT04800237
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vanda Pharmaceuticals
Industry
Enrollment
230 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • VQW-765 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 22, 2021
Primary completion
Aug 1, 2022
Completion
Aug 1, 2022
Last update posted
Mar 19, 2024

2021 – 2022

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Vanda Investigational Site Tempe Arizona 85281
Vanda Investigational Site Beverly Hills California 90212
Vanda Investigational Site Garden Grove California 92845
Vanda Investigational Site San Jose California 95124
Vanda Investigational Site Torrance California 90502
Vanda Investigational Site Orlando Florida 32816
Vanda Investigational Site Boston Massachusetts 02114
Vanda Investigational Site North Dartmouth Massachusetts 02747
Vanda Investigational Site Las Vegas Nevada 89119
Vanda Investigational Site Berlin New Jersey 08009
Vanda Investigational Site New York New York 10016
Vanda Investigational Site Staten Island New York 10312
Vanda Investigational Site Raleigh North Carolina 27612
Vanda Investigational Site Cincinnati Ohio 45212
Vanda Investigational Site Houston Texas 77074

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04800237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2024 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04800237 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →